Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02491359 · ClinicalTrials.gov registry record · Phase 2
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT02491359: Completed Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.
NCT02491359 is a Phase 2 study of Chronic Graft Versus Host Disease that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 20 participants, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02491359, a Phase 2 study of Chronic Graft Versus Host Disease, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cells damage the host tissue. Carfilzomib may be an effective treatment for chronic graft-versus-host disease.
Primary Outcome
according to National Cancer Institute CTCAE, version 4.03
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Carfilzomib
Study Locations (5)
Florida
- Moffitt Cancer Center - Tampa
New York
- Roswell Park Cancer Institute - Buffalo
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-11-12 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 2 |
What the finished NCT02491359 record still lists
NCT02491359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02491359 lists 5 locations in 5 states (Florida, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT02491359 about?
NCT02491359 is a clinical study titled "Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease". This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cel...
What is the current status of trial NCT02491359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-11-12. Estimated completion is 2018-09-12.
What conditions does trial NCT02491359 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.
What interventions are being tested in trial NCT02491359?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT02491359?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02491359 being conducted?
This trial has 5 study locations across Florida, New York, Ohio, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02491359's enrollment target sits among peer trials
20 25th of 30 higher than 5 of 30 other Chronic Graft Versus Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
RECRUITING · Phase 2
-
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
RECRUITING · Phase 2
-
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI